

905

GP/1648

**ATTORNEY'S DOCKET NUMBER: 2002850-0009 (S98-161 CIP II)  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**RECEIVED**

MAY 02 2002

Applicant: Founq *et al.*  
Serial No.: 09/728,720  
Filed: December 1, 2000  
For: PREVENTION AND TREATMENT OF HCV INFECTION EMPLOYING  
ANTIBODIES DIRECTED AGAINST CONFORMATIONAL EPITOPES

Examiner: Wortman, D.  
Art Group: 1648

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RECEIVED**

JUN 06 2002

COPY OF PAPERS  
ORIGINALLY FILED

TECH CENTER 1600/2900

**TRANSMITTAL LETTER**

Enclosed please find the following documents regarding the above-referenced matter:

- 1) Response to Restriction/Election Requirement (1 page);
- 2) Second Preliminary Amendment (3 pages), together with Appendix 1, Version with Markings to Show Changes Made (2 pages), and Appendix 2, Claims Pending After Entrance of Present Amendment (5 pages);
- 3) Return Postcard.

Please charge any fees or credit any overpayments to our Deposit Account No. 03-1721.

Respectfully submitted,


REG. # 44,332

Date: 4/22/02

Karoline K M Shaw FOR  
Brenda Herschbach Jarrell, Ph.D.  
Registration Number: 39,233

CHOATE, HALL & STEWART  
Exchange Place  
53 State Street  
Boston, MA 02109  
Tel: (617) 248-5000  
Facsimile: (617) 248-4000

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as first  
class mail in an envelope addressed to: Assistant  
Commissioner For Patents, Washington, D.C. 20231  
on April 22, 2002  
Ruby Hart Hagman



ATTORNEY'S DOCKET NUMBER: 2002850-0009 (S98-161 US CIP II)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Fount *et al.*

Serial No.: 09/728,720

Filed: December 1, 2000

For: PREVENTION AND TREATMENT OF HCV INFECTION EMPLOYING  
ANTIBODIES DIRECTED AGAINST CONFORMATIONAL EPITOPES

Examiner: Wortman, D

Art Unit: 1648

TECH CENTER 1600/2900

RECEIVED

MAY 3/2 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, DC 20231

COPY OF PAPERS  
ORIGINALLY FILED

Sir:

**RESPONSE TO RESTRICTION/ELECTION REQUIREMENT**

Responsive to the Restriction Requirement mailed March 22, 2002 (Paper Number 8), Applicant respectfully elects Group II (claims 1, 3-23, 25-32, 66, 67, and 70), drawn to antibodies specific for HCV E2 epitopes, corresponding pharmaceutical applications, and corresponding cell lines, classified in class 530, subclass 388.3 e.g.

Applicant thanks the Examiner for careful consideration of this case. Please charge any fees that may be associated with this matter, or credit any overpayments, to our Deposit Account No. 03-1721.

Respectfully submitted, Reg # 44,332

*Brenda Hershbach Jarrell*

Brenda Hershbach Jarrell, PhD.

Reg. No. 39,223

Choate, Hall & Stewart  
Exchange Place  
53 State Street  
Boston, MA 02109  
Tel: (617) 248-5000  
Dated: April 22, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 22, 2002  
*Kirkley West Hognor*

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900



COPY OF PAPERS  
ORIGINALLY FILED

#12  
Suppl. Amended  
RECEIVED  
MAY 02 2002

ATTORNEY DOCKET NUMBER: 2002850-0009 (S98-161 US CIP II)  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: Fount, et al.

Examiner: Wortman, D.

Serial No.: 09/728,720

Art Unit: 1648

Filed: December 1, 2000

For: PREVENTION AND TREATMENT OF HCV INFECTION EMPLOYING  
ANTIBODIES DIRECTED AGAINST CONFORMATIONAL EPITOPES

RECEIVED  
JUN 06 2002

Assistant Commissioner For Patents  
Washington, DC 20231

TECH CENTER 1600/2900

Sir:

SECOND PRELIMINARY AMENDMENT

Applicants submit the following second Preliminary Amendment and Remarks.

AMENDMENT

In the Claims:

Cancel claims 2, 24, 33-65, 68, 69, and 71-74.

Add claims 75-83.

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

75. A combination of two or more antibodies directed to one or more conformational epitopes of E2 protein of Hepatitis C virus.

76. The combination of two or more antibodies of claim 75, wherein the combination results in increased binding of the antibodies to one or more conformational epitopes of E2 protein of Hepatitis C virus.

77. The combination of two or more antibodies of claim 76, wherein the increased binding of two or more antibodies to the one or more conformational epitopes of E2 protein of Hepatitis C virus is greater than 100% relative to the binding of a single antibody.

78. The combination of two or more antibodies of claim 75 comprising CBH-7 and CBH-4G.